February 18, 2022 – Cue Health Inc. and Cardinal Health announced expanded distribution of Cue’s professional use and over the counter COVID-19 tests.
Cue selected Cardinal Health, which serves nearly 90% of US hospitals and over 60,000 pharmacies, as one of its primary distributors due to a demonstrated expertise in helping commercialize diagnostic technologies. This relationship will help accelerate the reach of Cue’s innovative nucleic acid amplification test (NAAT) into both traditional and non-traditional healthcare settings.
Health professionals and other qualified point-of-care test users can now purchase the Cue Health Monitoring System, the Cue COVID-19 Test for CLIA Certified Healthcare Providers and Laboratories (Professional), and Cue COVID-19 Test Positive Control Swabs and Test Negative Control Swabs through the vast Cardinal Health laboratory distribution network. An independent study by Mayo Clinic showed Cue’s COVID-19 test to be in 97.8% overall concordance with central lab PCR testing.
Additionally, the Cue COVID-19 Test for Home and Over the Counter (OTC) Use (OTC/Home) – the first molecular diagnostic test of any kind available for use at home or in other non-clinical settings without a prescription to receive Emergency Use Authorization (EUA) from the FDA – is also available through Cardinal Health. Cue’s molecular OTC/home test is the most accurate COVID-19 self-test*, can be used on adults and children (2 years and over) with or without symptoms, and is available for use at home or in other non-clinical settings without a prescription.